These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17343904)

  • 1. Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
    Ohishi Y; Oda Y; Basaki Y; Kobayashi H; Wake N; Kuwano M; Tsuneyoshi M
    Gynecol Oncol; 2007 Jun; 105(3):586-92. PubMed ID: 17343904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
    Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
    Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M
    Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
    BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
    Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
    Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
    Galmarini CM; Treilleux I; Cardoso F; Bernard-Marty C; Durbecq V; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A; Dumontet C
    Clin Cancer Res; 2008 Jul; 14(14):4511-6. PubMed ID: 18628466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
    Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
    Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I; Lindborg K; Sorbe B
    Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
    Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
    J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
    Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
    Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.
    Roque DM; Buza N; Glasgow M; Bellone S; Bortolomai I; Gasparrini S; Cocco E; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
    Clin Exp Metastasis; 2014 Jan; 31(1):101-10. PubMed ID: 24005572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
    Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
    Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.